Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Healthy
Interventions: Zidovudine tablets 300 mg; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Inflammatory Disease
Interventions: Lanraplenib.; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida

Conditions: Major Depressive Disorder
Interventions: LY03005, Pristiq; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: divalproex sodium, Depakote®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hypogonadism
Interventions: Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose); Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 68 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • San Antonio, Texas

Conditions: Child Disruptive Behavior Disorders, Parent Child Relationship, Parent Management Training, Peer Support, Child Behavior Problems, Challenging Behavior, Positive Parenting
Interventions: FAST-B PEERS, FAST-B (First Approach Skills Training - Behavior); Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Gout
Interventions: D-0120; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Bioavailability
Interventions: Naproxen sodium; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Healthy
Interventions: Decitabine; Drug
Lead sponsor: EpiDestiny, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Concussion, Brain
Interventions: Osteopathic manipulative treatment, Usual care; Procedure
Lead sponsor: Michigan State University; Other
Eligibility: 13 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Trichomonas Vaginalis
Interventions: Point of care tests; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years to 35 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pancreatitis, Pancreatitis, Acute, Pancreatitis, Chronic, Pancreas Disease, Acute Recurrent Pancreatitis
Interventions: Intermittent Fasting, No intermittent fasting; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions: Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 4
States / cities: Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more

Conditions: Pulmonary Disease, Critical Illness
Interventions: There is no intervention in this observational study; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hepatitis C
Interventions: interferon alfa-2b, peginterferon alfa-2b, ribavirin, USP, external drug infusion pump; Drug · Device
Lead sponsor: Medtronic Corporate Technologies and New Ventures; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Terbinafine Hydrochloride Tablets 250 mg, Lamisil® Tablets 250 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions: Not listed
Lead sponsor: Hektoen Institute for Medical Research; Other
Eligibility: 15 Years to 24 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Denver, Colorado • Chicago, Illinois • Philadelphia, Pennsylvania

Conditions: Obesity, Childhood, Asthma in Children, Inflammatory Response, Metabolic Syndrome, Nutrition Poor, Physical Activity, Behavior, Eating, Molecular Biology, Restriction Fragment Length Polymorphisms, Maternal Exposure, Genetic Change
Interventions: Lifestyle counseling; Behavioral
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 13 Years to 19 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Breast Cancer, Metastatic Breast Cancer
Interventions: Prolonged Nightly Fasting, Exercise; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatic Impairment
Interventions: Omaveloxolone 50 mg capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Tustin, California • Miami, Florida • Orlando, Florida

Conditions: Stroke, Acute
Interventions: Direct to Angio Suite (DTAS) Philips' CBCT triage, Conventional CT/MR triage; Device · Procedure
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Jacksonville, Florida • Atlanta, Georgia • The Bronx, New York

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions: Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Asthma
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Active Females
Interventions: Beta-hydroxy beta-methylbutyrate, Resistance Training, Protein Supplementation, Time-Restricted Feeding; Dietary Supplement · Other · Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lubbock, Texas

Search by objective public record fields.

Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions

Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function

A Study of LY03005 vs Pristiq

Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions

Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men

Examining the Feasibility, Acceptability, and Fidelity of Utilizing Parent Training Graduates as Peer Supports

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

Fast & Fed Pharmacokinetic (PK) Study

Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects

The Role of Osteopathic Manipulative Medicine in Recovery From Concussions

Accuracy and Acceptability of Self-Diagnostic Methods for Vaginitis in Adolescent Females

Intermittent Fasting for Pancreatitis

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C

Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - Intervention Development

Asthma and Obesity Diet Versus Exercise

Feasibility of Fasting & Exercise in Pts With HR+ MBC

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

Effect of Fasting on the Asthma Inflammasome

Time-Restricted Feeding Plus Resistance Training in Active Females